520 related articles for article (PubMed ID: 31537547)
1. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
He J; Zhang R; Shao M; Zhao X; Miao M; Chen J; Liu J; Zhang X; Zhang X; Jin Y; Wang Y; Zhang S; Zhu L; Jacob A; Jia R; You X; Li X; Li C; Zhou Y; Yang Y; Ye H; Liu Y; Su Y; Shen N; Alexander J; Guo J; Ambrus J; Lin X; Yu D; Sun X; Li Z
Ann Rheum Dis; 2020 Jan; 79(1):141-149. PubMed ID: 31537547
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
3. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Humrich JY; Cacoub P; Rosenzwajg M; Pitoiset F; Pham HP; Guidoux J; Leroux D; Vazquez T; Riemekasten G; Smolen JS; Tsokos G; Klatzmann D
Ann Rheum Dis; 2022 Dec; 81(12):1685-1694. PubMed ID: 35973803
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Isenberg DA; Petri M; Kalunian K; Tanaka Y; Urowitz MB; Hoffman RW; Morgan-Cox M; Iikuni N; Silk M; Wallace DJ
Ann Rheum Dis; 2016 Feb; 75(2):323-31. PubMed ID: 26338095
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Merrill JT; van Vollenhoven RF; Buyon JP; Furie RA; Stohl W; Morgan-Cox M; Dickson C; Anderson PW; Lee C; Berclaz PY; Dörner T
Ann Rheum Dis; 2016 Feb; 75(2):332-40. PubMed ID: 26293163
[TBL] [Abstract][Full Text] [Related]
6. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
[TBL] [Abstract][Full Text] [Related]
7. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M
Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB
Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S
Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124
[TBL] [Abstract][Full Text] [Related]
13. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Isenberg D; Furie R; Jones NS; Guibord P; Galanter J; Lee C; McGregor A; Toth B; Rae J; Hwang O; Desai R; Lokku A; Ramamoorthi N; Hackney JA; Miranda P; de Souza VA; Jaller-Raad JJ; Maura Fernandes A; Garcia Salinas R; Chinn LW; Townsend MJ; Morimoto AM; Tuckwell K
Arthritis Rheumatol; 2021 Oct; 73(10):1835-1846. PubMed ID: 34042314
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
[TBL] [Abstract][Full Text] [Related]
16. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.
Zimmer R; Scherbarth HR; Rillo OL; Gomez-Reino JJ; Muller S
Ann Rheum Dis; 2013 Nov; 72(11):1830-5. PubMed ID: 23172751
[TBL] [Abstract][Full Text] [Related]
17. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
18. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
[TBL] [Abstract][Full Text] [Related]
19. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
Isenberg D; Gordon C; Licu D; Copt S; Rossi CP; Wofsy D
Ann Rheum Dis; 2015 Nov; 74(11):2006-15. PubMed ID: 24951103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
